Managing Subdural Bleeding Associated With Rivaroxaban: A Series of 3 Cases

Objective: To report 3 cases of subdural bleeding associated with rivaroxaban managed by 3-factor prothrombin complex concentrate (PCC3). Case Summaries: Case 1 presented with a 1-cm thick subdural hematoma (SDH) 12 hours after her last dose of rivaroxaban. Case 2 presented with a right 1-cm acute r...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmacy practice 2016-06, Vol.29 (3), p.257-262
Main Authors: Faust, Andrew C., Woodard, Sarah, Koehl, Jennifer L., Mees, William, Steinke, Douglas, Denetclaw, Tina Harrach
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Animals
Blood Coagulation Factors - therapeutic use
Disease Management
Factor Xa Inhibitors - adverse effects
Female
Hematoma, Subdural - chemically induced
Hematoma, Subdural - diagnosis
Hematoma, Subdural - drug therapy
Hemorrhage - chemically induced
Hemorrhage - diagnosis
Hemorrhage - drug therapy
Humans
Male
Rivaroxaban - adverse effects
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: To report 3 cases of subdural bleeding associated with rivaroxaban managed by 3-factor prothrombin complex concentrate (PCC3). Case Summaries: Case 1 presented with a 1-cm thick subdural hematoma (SDH) 12 hours after her last dose of rivaroxaban. Case 2 presented with a right 1-cm acute right SDH with 2 to 3 mm of midline shift 24 hours after his last dose of rivaroxaban. Case 3 presented with a 1.8-cm thick right cerebral convexity hematoma 12 hours after her last dose of rivaroxaban. All patients received 23 to 35 units/kg PCC3 with 1 to 3 units of fresh frozen plasm (FFP) and demonstrated no progression in lesions measured by repeat computed tomography (CT). Two patients were discharged to rehabilitation facilities and 1 patient ultimately died due to the location of the lesion. Discussion: Rivaroxaban has no specific antidote. Current bleeding management strategies are based on expert opinion. The risks and benefits for differing strategies are unclear, and no clinical experience has been reported to date. These cases begin to illuminate differences among choices for managing bleeding associated with Xa inhibitors. Conclusion: In this case series, 25 to 35 units/kilogram PCC3 and FFP 1 to 3 units ceased rivaroxaban-associated bleeding without thrombogenic complications.
ISSN:0897-1900
1531-1937
DOI:10.1177/0897190015627116